140 filings
6-K
MDNAF
Medicenna Therapeutics Corp.
13 May 24
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
2:30pm
6-K
MDNAF
Medicenna Therapeutics Corp.
30 Apr 24
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
3:07pm
6-K
MDNAF
Medicenna Therapeutics Corp.
26 Apr 24
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
3:28pm
6-K
MDNAF
Medicenna Therapeutics Corp.
25 Apr 24
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
2:00pm
6-K
MDNAF
Medicenna Therapeutics Corp.
9 Apr 24
Current report (foreign)
8:44pm
6-K
fxwom6g
9 Apr 24
Current report (foreign)
2:05pm
6-K
jtqkax37vfc
4 Apr 24
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
2:00pm
6-K
tho8o
6 Mar 24
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
11:00am
6-K
vdlky
14 Feb 24
Interim condensed consolidated financial statements of
7:30am
6-K
lip4rh
13 Feb 24
Current report (foreign)
10:30am
6-K
8dv505ucq ug
24 Jan 24
Notice of Change of Auditor
4:00pm
6-K
s6oklsn8
12 Jan 24
Medicenna Announces Appointment of New Auditor
7:15pm
6-K
ii7uy vzetxm835
9 Jan 24
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
10:33am
6-K
ys9g985s8hcpxap0687l
5 Jan 24
Notice of Change of Auditor
9:06am
6-K
jljb njxs4up6
22 Dec 23
Current report (foreign)
2:13pm
6-K
8fhr0h7w5o
21 Dec 23
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
7:31pm
6-K
xj2uv fye4878v
21 Nov 23
Current report (foreign)
10:39am
6-K
fy4s9fogn7qdurqnh3o
14 Nov 23
Interim condensed consolidated financial statements of
12:00am
6-K
ou5pm b9i16
8 Nov 23
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
10:29am
6-K
t0o18xk1qdo9d1at
25 Oct 23
Current report (foreign)
3:51pm